IP Verse

Cell - EP3237442

The patent EP3237442 was granted to Autolus on Jul 10, 2019. The application was originally filed on Dec 23, 2015 under application number EP15817520A. The patent is currently recorded with a legal status of "Revoked".

EP3237442

AUTOLUS
Application Number
EP15817520A
Filing Date
Dec 23, 2015
Status
Revoked
Jul 1, 2022
Grant Date
Jul 10, 2019
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions (2)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

JAMES POOLEApr 9, 2020CARPMAELS & RANSFORDADMISSIBLE
MILTENYI BIOTECApr 8, 2020HEIDEADMISSIBLE

Patent Citations (20) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication NumberPublication Link
INTERNATIONAL-SEARCH-REPORTWO2013123061
INTERNATIONAL-SEARCH-REPORTWO2014065961
INTERNATIONAL-SEARCH-REPORTWO2014124143
INTERNATIONAL-SEARCH-REPORTWO2015075468
OPPOSITIONGB1507111
OPPOSITIONUS2013287748
OPPOSITIONUS9868774
OPPOSITIONWO2013123061
OPPOSITIONWO2013185552
OPPOSITIONWO2014055657
OPPOSITIONWO2014055668
OPPOSITIONWO2014065961
OPPOSITIONWO2014124143
OPPOSITIONWO2014138704
OPPOSITIONWO2014145252
OPPOSITIONWO2015075468
OPPOSITIONWO2015092024
OPPOSITIONWO2015142314
OPPOSITIONWO2016174405
OPPOSITIONWO2016210293

Non-Patent Literature (NPL) Citations (46) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference TextLink
EXAMINATION- Haiying Qin ET AL, "Preclinical Development of Bispecific Chimeric Antigen Receptor Targeting Both CD19 and CD22 | Blood Journal", Blood, (20150101), page 4427, URL: http://www.bloodjournal.org/content/126/23/4427?sso-checked=true, (20181022), XP055517725-
EXAMINATION- Qin, "Novel CD19/CD22 Bicistronic Chimeric Antigen Receptors Outperform Single or Bivalent Cars in Eradicating CD19+CD22+, CD19-, and CD22- Pre-B Leukemia | Blood Journal", (20171207), URL: http://www.bloodjournal.org/content/130/Suppl_1/810?sso-checked=true, (20180712), XP055492275-
EXAMINATION- Qin Haiying; Haso Waleed; Sang Minh Nguyen; Fry Terry J, "4427: Preclinical Development of Bispecific Chimeric Antigen Receptor Targeting Both CD19 and CD22", BLOOD, US, (20151203), vol. 126, no. 23, ISSN 0006-4971, page 4427, XP055274953
INTERNATIONAL-SEARCH-REPORT- Tobias Riët, "Erhöhung der Antigen-Selektivität von T-Zellen durch Koexpression chimärer Antigen- Rezeptoren unterschiedlicher Spezifität Inaugural-Dissertation zur Erlangung des Doktorgrades der Mathematisch-Naturwissenschaftlichen Fakultät der Universität zu Köln vorgelegt von", (20101124), URL: file:///C:/Users/SO51107/AppData/Local/Temp/Dissertation-TobiasRiet-2.pdf, (20160222), XP055252275 [Y] 1-21,28-31 * page 76, paragraph 1 * * page 104 *-
INTERNATIONAL-SEARCH-REPORT- SCOTT WILKIE ET AL, "Dual Targeting of ErbB2 and MUC1 in Breast Cancer Using Chimeric Antigen Receptors Engineered to Provide Complementary Signaling", JOURNAL OF CLINICAL IMMUNOLOGY, KLUWER ACADEMIC PUBLISHERS-PLENUM PUBLISHERS, NE, (20120417), vol. 32, no. 5, doi:10.1007/S10875-012-9689-9, ISSN 1573-2592, pages 1059 - 1070, XP035113362 [Y] 1-21,28-31 * the whole document * * figure 1 *
INTERNATIONAL-SEARCH-REPORT- JENA BIPULENDU ET AL, "Driving CAR-Based T-Cell Therapy to Success", CURRENT HEMATOLOGIC MALIGNANCY REPORTS, CURRENT SCIENCE INC., PHILADELPHIA, PA, US, vol. 9, no. 1, doi:10.1007/S11899-013-0197-7, ISSN 1558-8211, (20140202), pages 50 - 56, (20140202), XP035330171 [Y] 1-21,28-31 * the whole document * * page 51, column r *
INTERNATIONAL-SEARCH-REPORT- SHIVANI SRIVASTAVA ET AL, "Engineering CAR-T cells: Design concepts", TRENDS IN IMMUNOLOGY, GB, (20150801), vol. 36, no. 8, doi:10.1016/j.it.2015.06.004, ISSN 1471-4906, pages 494 - 502, XP055251965
INTERNATIONAL-SEARCH-REPORT- HEGDE M ET AL, "Combinational targeting offsets antigen escape and enhances effector functions of adoptively transferred T cells in glioblastoma", MOLECULAR THERAPY, NATURE PUBLISHING GROUP, GB, vol. 21, no. 11, doi:10.1038/MT.2013.185, ISSN 1525-0024, (20131101), pages 2087 - 2101, (20130813), XP002725708 [Y] 1-21,28-31 * the whole document *
INTERNATIONAL-SEARCH-REPORT- E. LANITIS ET AL, "Chimeric Antigen Receptor T Cells with Dissociated Signaling Domains Exhibit Focused Antitumor Activity with Reduced Potential for Toxicity In Vivo", CANCER IMMUNOLOGY RESEARCH, (20130407), vol. 1, no. 1, doi:10.1158/2326-6066.CIR-13-0008, ISSN 2326-6066, pages 43 - 53, XP055170367 [Y] 1-21,28-31 * the whole document *
INTERNATIONAL-SEARCH-REPORT- DUONG CONNIE PM ET AL, "Enhancing the specificity of T-cell cultures for adoptive immunotherapy of cancer", IMMUNOTHERAPY, FUTURE MEDICINE, LONDON, (20110101), vol. 3, no. 1, doi:10.2217/IMT.10.81, ISSN 1750-7448, pages 33 - 48, XP008175032 [Y] 1-21,28-31 * the whole document *
OPPOSITION- GHETIE et al., "The Antitumor Activity of an Anti- CD 22 Immunotoxin in SCID Mice D22 With Disseminated Daudi Lymphoma Is Enhanced by Either an Anti- CD 19 Antibody or an Anti- CD 19 Immunotoxin", Blood., (19920000), vol. 80, no. 9, pages 2315 - 2320, XP055105058-
OPPOSITION- LOHMUELLER J., "Synthetic Biology Approaches to Engineering Human Cells", Doctoral dissertation, Harvard University, (20130000), XP055794149-
OPPOSITION- TOBIAS RIET, Erhohung der Antigen-Selektivitat von T-Zellen durch Koexpression chimarer Antigen-Rezeptoren unterschiedlicher Spezifitat Inaugural-Dissertation zur Erlangung des Doktorgrades der Mathematisch-Naturwissenschaftlichen Fakultat der Universitat zu Koln vorgelegt von, (20101124), XP055252275-
OPPOSITION- WILKIE et al., "Dual Targeting of ErbB2 and MUC1 in Breast Cancer Using Chimeric Antigen Receptors Engineered to Provide Complementary Signaling", JOURNAL OF CLINICAL IMMUNOLOGY, KLUWER ACADEMIC PUBLISHERS-PLENUM PUBLISHERS, NE, (20120417), vol. 32, no. 5, doi:10.1007/s10875-012-9689-9, XP035113362
OPPOSITION- WILKIE et al., "Dual Targeting of ErbB2 and MUC1 in Breast Cancer Using D27 Chimeric Antigen Receptors Engineered to Provide Complementary Signaling", J Clin Immunol., (20120000), vol. 32, doi:10.1007/s10875-012-9689-9, pages 1059 - 1070, XP035113362
OPPOSITION- JENA et al., "Driving CAR-Based T- Cell Therapy to Success", CURRENT HEMATOLOGIC MALIGNANCY REPORTS, PHILADELPHIA, PA, US, (20140202), vol. 9, no. 1, doi:10.1007/s11899-013-0197-7, XP035330171
OPPOSITION- JENA et al., "Driving CAR-Based T- Cell Therapy to Success", Curr Hematol Malig Rep., (20140000), vol. 9, no. 1, doi:10.1007/s11899-013-0197-7, pages 50 - 56, XP035330171
OPPOSITION- KUMARESAN et al., "180 Dual-Specificity CAR+ T Cells to Target B-Cell Malignanciesand Opportunistic Fungal Infection", Biol Blood Marrow Transplant, (20140000), vol. 10, no. 2 Supp 1, page s132, XP028828134
OPPOSITION- QIN et al., "Preclinical Development of Bivalent Chimeric Antigen Receptors Targeting Both CD19 and CD22", Mol Ther Oncolytics, (20181200), vol. 11, page 127, XP055770751
OPPOSITION- HEDGE et al., "Combinational targeting offsets antigen escape and enhances effector functions of adoptively transferred T cells in glioblastoma", MOLECULAR THERAPY, GB, (20131101), vol. 21, no. 11, doi:10.1038/mt.2013.185, XP002725708
OPPOSITION- HEGDE et al., "Combinational Targeting Offsets Antigen Escape and Enhances 08 Effector Functions of Adoptively Transferred T Cells in Glioblastoma", Molecular Therapy, (20130000), vol. 21, no. 11, doi:10.1038/mt.2013.185, pages 2087 - 2101, XP002725708
OPPOSITION- Christopher C Kloss, Maud Condomines, Marc Cartellieri, Michael Bachmann, Michel Sadelain, "Combinatorial antigen recognition with balanced signaling promotes selective tumor eradication by engineered T cells", Nature Biotechnology, Gale Group Inc., New York, us, us, (20130101), vol. 31, no. 1, doi:10.1038/nbt.2459, ISSN 1087-0156, pages 71 - 75, XP055130697
OPPOSITION- BRENTJENS et al., "Eradication of systemic B- cell tumors by genetically targeted D15 human T lymphocytes co-stimulated by CD 80 and interleukin-15", Nature Medicine, (20030000), vol. 9, no. 3, doi:10.1038/nm827, pages 279 - 286, XP002389127
OPPOSITION- MACKALL et al., "Immune-based therapies for childhood cancer", Nat Rev Clin Oncol., (20141028), vol. 11, no. 12, doi:10.1038/nrclinonc.2014.177, pages 693 - 703, XP055493874
OPPOSITION- MACKAL L et al., "Immune-based therapies for childhood cancer", Nature Reviews, Clinical Oncology, (20140000), vol. 11, doi:10.1038/nrclinonc.2014.177, pages 693 - 703, XP055493874
OPPOSITION- LIU et al., "Systematic comparison of 2A peptides for cloning multi-genes ina polycistronic vector", Nature Sci Rep, (20170519), vol. 7, no. 1, XP055515282
OPPOSITION- KUMARESAN et al., "Bioengineering T cells to target carbohydrate to treat opportunistic fungal infectio", PNAS, (20140722), vol. 111, no. 29, pages 10660 - 10665, XP055309114
OPPOSITION- PEGRAM et al., "CD 28z CARs and Armored CARs", Cancer J., vol. 20, no. 2, doi:10.1097/PPO.0000000000000034, (20140301), pages 127 - 133, XP055247596
OPPOSITION- DOTTI et al., "Design and Development of Therapies using Chimeric Antigen Receptor-Expressing T cells", Immunol Rev., (20140000), vol. 257, no. 1, doi:10.1111/imr.12131, pages 1 - 35, XP055552726
OPPOSITION- JENSEN et al., "Design and implementation of adoptive therapy with chimeric antigen receptor-modified T cells", Immunol Rev., vol. 257, no. 1, doi:10.1111/imr.12139, (20131213), pages 127 - 144, XP055533644
OPPOSITION- FEDOROV et al., "PD-1 and CTLA-4 Based Inhibitory Chimeric Antigen Receptors D10 (iCARs) Divert Off-Target Immunotherapy Responses", Science Translational Medicine, (20130000), vol. 5, no. 215, doi:10.1126/scitranslmed.3006597, pages 1 - 12, XP055210508
OPPOSITION- SHI et al., "Chimeric antigen receptor for adoptive immunotherapy of cancer: latest research and future prospects", Molecular Cancer., (20140000), vol. 13, no. 219, doi:10.1155/2019/6729701, pages 1 - 8, XP055565409
OPPOSITION- VALLERA DANIEL A, ET AL, "A bispecific recombinant immunotoxin, DT2219, targeting human CD19 and CD22 receptors in a mouse xenograft model of B-cell leukemia/lymphoma.", CLINICAL CANCER RESEARCH, American Association for Cancer Research, US, US, (20050515), vol. 11, no. 10, doi:10.1158/1078-0432.CCR-04-2290, ISSN 1078-0432, pages 3879 - 3888, XP002425289
OPPOSITION- LANITIS et al., "Chimeric Antigen Receptor T cells with Dissociated Signaling D26 Domains Exhibit Focused Antitumor Activity with Reduced Potential for Toxicity In Vivo", Cancer Immunology Research, (20130000), vol. 1, no. 1, doi:10.1158/2326-6066.CIR-13-0008, pages 43 - 53, XP055170367
OPPOSITION- LANITIS et al., "Chimeric Antigen Receptor T Cells with Dissociated Signaling Domains Exhibit Focused Antitumor Activity with Reduced Potential for Toxicity in Vivo", CANCER IMMUNOLOGY RESEARCH, (20130407), vol. 1, no. 1, XP055170306
OPPOSITION- HUDECEK et al., "The Nonsignaling Extracellular Spacer Domain of Chimeric Antigen Receptors Is Decisive for In Vivo Antitumor Activity", Cancer Immunology Research., (20150000), vol. 3, no. 2, doi:10.1158/2326-6066.CIR-14-0127, pages 125 - 135, XP055177300
OPPOSITION- S. L. Maude, E. J. Shpall, S. A. Grupp, "Chimeric antigen receptor T-cell therapy for ALL", HEMATOLOGY, AMERICAN SOCIETY OF HEMATOLOGY, WASHINGTON, DC, US, US, (20141201), vol. 2014, no. 1, doi:10.1182/asheducation-2014.1.559, ISSN 1520-4391, pages 559 - 564, XP055439390
OPPOSITION- HASO et al., "Anti- CD 22-chimeric antigen receptors targeting B- cell precursor acute lymphoblastic leukemia", Blood, vol. 121, no. 7, (20121214), pages 1165 - 1174, XP009173973
OPPOSITION- Haso Waleed et al, "Anti-CD22-chimeric antigen receptors targeting B-cell precursor acute lymphoblastic leukemia", BLOOD, The American Society of Hematology, US, US, (20130201), vol. 121, no. 7, doi:10.1182/blood-2012-06-438002, ISSN 0006-4971, pages 1165 - 1174, XP009173973
OPPOSITION- Edmund A. Rossi, Chang Chien-Hsing, Goldenberg David, Bachmann Michael, "Anti-CD22/CD20 Bispecific Antibody with Enhanced Trogocytosis for Treatment of Lupus", PLoS ONE, Public Library of Science, vol. 9, no. 5, doi:10.1371/journal.pone.0098315, page e98315, XP055251505
OPPOSITION- DUONG et al., "Enhancing the specificity of T- cell cultures for adoptive immunotherapy of cancer", Immunotherapy , Future Medicine, London, (20110101), vol. 3, no. 1, doi:10.2217/imt.10.81, XP008175032
OPPOSITION- Leonardo Chicaybam, "Moving receptor redirected adoptive cell therapy toward fine tuning of antitumor responses", Int Rev Immunol ., (20140101), vol. 33, pages 402 - 416, XP055745388
OPPOSITION- Rimas J. Orentas, Daniel W. Lee, Crystal Mackall, "Immunotherapy Targets in Pediatric Cancer", Frontiers in Oncology, vol. 2, doi:10.3389/fonc.2012.00003, XP055170174
OPPOSITION- JAMES et al., "Antigen Sensitivity of CD 22-Specific Chimeric TCR Is Modulated by D20 Target Epitope Distance from the Cell Membrane", The Journal of Immunology, (20080000), vol. 180, doi:10.4049/jimmunol.180.10.7028, pages 7028 - 7038, XP002679899
OPPOSITION- LONG et al., "Lessons learned from a highly-active CD 22-specific chimeric antigen receptor", Oncoimmunology, vol. 2, no. 4, doi:10.4161/onci.23621, (20130401), page e23621, XP009173972
OPPOSITION- John Maher, "Immunotherapy of Malignant Disease Using Chimeric Antigen Receptor Engrafted T Cells", ISRN Oncology, (20120101), vol. 29, no. s7, abstract 130, doi:10.5402/2012/278093, pages S33 - 23, XP055184892

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents